Abstract: A theatre construction comprises a seating area 120 for an audience, a circular support structure 134 surrounding the seating area and mounted above the seating area and a plurality of arcuate screens 135 suspended from the circular support structure. The screens 135 are mounted to the circular support structure 134 on rails for allowing movement of the screens about the seating area.
Abstract: A combination of a holder and a selfie stick of the present invention includes a case main body; an attachable disk attached to a back surface of the case main body; a case main body supporter formed of an attachable disk coupling part rotatably coupled to the attachable disk, and an extending part configured to extend from the attachable disk coupling part; a folding part hinge-coupled to the case main body supporter to be folded to be spaced apart from the case main body supporter; a folding part supporter elongated in a longitudinal direction of the folding part to support the folding part and serve as a holder and a handle; and a first extendable stick and a second extendable stick configured to space the folding part supporter apart from the folding part to serve as selfie sticks with the folding part and the folding part supporter.
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
July 20, 2021
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE CAEN NORMANDIE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN
Abstract: The method of the invention determines a physical characteristic on a punctual location inside a medium, and includes including the steps of sending an emitted sequence having emitted pulses that have different amplitudes, receiving a received sequence having received pulses corresponding to echoes of the emitted pulses, calculating a phase difference between the received pulses relative to the emitted pulses, and determining the physical characteristic on the punctual location on the bases of said the phase difference.
Abstract: Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/KI-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.
Abstract: A method for evaluating the quality of the measurement of an optical wavefront, said measurement being obtained by means of a wavefront analyzer by direct measurement, the method comprising: the acquisition (10) of an optoelectronic signal for the measurement of the wavefront by means of a wavefront sensor, said sensor comprising a two-dimensional detector; the determination (11) on the basis of said optoelectronic signal of at least one parameter characteristic of a parasitic component of the optoelectronic signal; the evaluation (12) of a quality factor of the measurement of the wavefront as a function of said at least one parameter characteristic of the parasitic component of the signal; the display (13) to a user of a level of quality of the measurement as a function of said quality factor.
Abstract: A theatre construction comprises a seating area (120) for an audience, a circular support structure (134) surrounding the seating area and mounted above the seating area and a plurality of arcuate screens (135) suspended from the circular support structure. The screens (135) are mounted to the circular support structure (134) on rails for allowing movement of the screens about the seating area.
Abstract: A playout system for providing playout of fragmented video content is provided. The system includes a non-transitory data store and a processor. The processor is configured to playout content for video origination using a fragmented format. The processor can receive a playlist and generate a plurality of video fragments from source content. A transcoder can process video fragments based on one or more program scheduling requirements from the playlist to generate new video fragments. A manifest is updated to reference the new video fragments. The process can output a video stream based on the new video fragments.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
May 4, 2021
Assignee:
IMAGINE COMMUNICATIONS CORP.
Inventors:
Stephen Smith, Yuval Fisher, Brick Eksten, Steven Reynolds
Abstract: A textile with an electrically conductive first side and an electrically conductive second side where the two sides are separated by an electrically insulating part of the textile and where the electrically conductivity is provided by a graphene coating on the respective sides and where a capacitance can be formed between the respective conductive sides.
Abstract: A textile with an electrically conductive first side and an electrically conductive second side where the two sides are separated by an electrically insulating part of the textile and where the electrically conductivity is provided by a graphene coating on the respective sides and where a capacitance can be formed between the respective conductive sides.
Abstract: The present invention relates to a hand-held microfluidic detection device, comprising: —a microfluidic cell (M) having at least one chamber intended to at least contain a sample; —a support (S) comprising a housing for the removable attachment thereto of the microfluidic cell (M); —excitation light means arranged at least in part in the support (S) to side illuminate the at least one chamber of the microfluidic cell (M) to excite the sample contained therein; —an optical detector (D) configured and arranged to detect light emitted from the sample when excited with said side illumination; and —a casing (C) constituting an envelope into which at least the support (S) is housed and attached.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
December 8, 2020
Assignees:
FUNDACIÓ INSTITUT DE CIÈNCIES FOTÒNIQUES, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, IMAGINE OPTIC SPAIN SL
Inventors:
Romain Quidant, Luis Miguel Fidalgo, Rafael Porcar
Abstract: A system includes a formatter configured to adapt media content that is stored in memory to a media delivery format that is compatible with a media delivery medium corresponding to transmission medium for delivery of the media content. A delivery manager is configured to process a request for the media content and deliver the media content in the media deliver format via the media delivery medium based on one of a delivery time constraint and a quality constraint. A weighing engine is configured to prioritize the delivery time constraint over the quality constraint for the media content or the quality constraint over the delivery time constraint for the media content based on a type of media content to deliver a timely version of the media content timely via the media delivery medium.
Abstract: A method for performing shear wave elastography imaging of an observation field in a medium, the method including shear wave imaging steps to acquire sets of shear wave propagation parameters, the method further including a reliability indicator determining step during which a reliability indicator of the shear wave elastography imaging of the observation field is determined.
Type:
Grant
Filed:
October 28, 2014
Date of Patent:
September 15, 2020
Assignee:
SUPER SONIC IMAGINE
Inventors:
Thanasis Loupas, Matthew Frederick Bruce, Aline Laure Criton
Abstract: Methods and apparatus for delivering video programs are provided. A plurality of video programs are provided in a fragmented, adaptive bit rate format. A request for a respective video program from the plurality of video programs is received from each of a plurality of clients. The requested video programs are multiplexed for delivery to the clients in a multiplex over a shared, fixed-bit-rate transmission channel. In the fragmented, adaptive bit rate format, the fragment delivered to the client may not be the same as the requested fragment and is dependent on multiple criteria, including the bitrate and quality of the requested and delivered fragments, the total available delivery bandwidth, and other fragment requests made on the channel. The resulting multiplex may be either a constant bit rate multiplex or a variable bit rate multiplex.
Abstract: A theatre construction comprises a seating area (120) for an audience, a circular support structure (134) surrounding the seating area and mounted above the seating area and a plurality of arcuate screens (135) suspended from the circular support structure. The screens (135) are mounted to the circular support structure (134) on rails for allowing movement of the screens about the seating area.
Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to one or more of SEQ ID No(s) 1, 2, 3 or 4. The therapeutically effective amount of polypeptide may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed are methods for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide according to SEQ ID Nos. 1-4.
Abstract: The present invention relates to a hand-held microfluidic detection device, comprising: a microfluidic cell (M) having at least one chamber intended to at least contain a sample; a support (S) comprising a housing for the removable attachment thereto of the microfluidic cell (M); excitation light means arranged at least in part in the support (S) to side illuminate the at least one chamber of the microfluidic cell (M) to excite the sample contained therein; an optical detector (D) configured and arranged to detect light emitted from the sample when excited with said side illumination; and a casing (C) constituting an envelope into which at least the support (S) is housed and attached.
Type:
Application
Filed:
July 3, 2018
Publication date:
July 16, 2020
Applicants:
FUNDACIÓ INSTITUT DE CIÈNCIES FOTÒNIQUES, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, IMAGINE OPTIC SPAIN SL
Inventors:
Romain Quidant, Luis Miguel Fidalgo, Rafael Porcar
Abstract: A system can comprise a memory for storing machine readable instructions and a processing unit for accessing the memory and executing the machine readable instructions. The machine readable instructions can comprise an automation client to facilitate managing media operations. The automation client can comprise a graphical user interface (GUI) generator to provide a GUI. The GUI can concurrently provide a plurality of modes of operation for a plurality of playlists in a graphical framework.
Type:
Grant
Filed:
November 13, 2017
Date of Patent:
June 30, 2020
Assignee:
IMAGINE COMMUNICATIONS CORP.
Inventors:
Michael J. Salyards, Charles P. Lotz, Csaba Felvegi
Abstract: The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis.
Type:
Grant
Filed:
November 16, 2016
Date of Patent:
May 19, 2020
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FONDATION IMAGINE, UNIVERSITÉ PARIS DESCARTES ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Pascale De Lonlay-Debeney, Corinne Lebreton, Yamina Hamel, Francois-Xavier Mauvais, Peter Van Endert
Abstract: As one example, a method includes analyzing profile metadata for each of a plurality of ABR program streams within a lookahead window from a current chunk boundary to identify at least one target event at a chunk boundary. ABR profiles for chunks at the target event chunk boundary are allocated to fit within the channel bandwidth and achieve a predetermined target quality level for the chunks at the target event chunk boundary. In response to each target event, ABR profiles for each of the unallocated chunks within the lookahead window are selected by adjusting the ABR profiles for each of the unallocated chunks to fit within the predetermined bandwidth constrained by the ABR profiles allocated for the chunks at the target event chunk boundary. An ABR profile for a given chunk at the current chunk boundary is allocated based on the selected ABR profiles.